Piper Jaffray upgraded Exelixis (NASDAQ: EXEL) from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Upgrades

Leerink Bumps PT on Exelixis (EXEL) Up to $16 Following Latest Cabozantinib DataOctober 11, 2016 6:27 AM Exelixis (EXEL) Bullish View Reiterated at Leerink Following Positive CABOSUN DataOctober 10, 2016 7:40 AM Exelixis (EXEL) Announces Statistically Significant Data from Cabozantinib Phase 2 in RCCOctober 10, 2016 6:16 AM Ipsen and Its Partner Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at the European SocOctober 10, 2016 2:16 AM Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016October 10, 2016 2:15 AM Exelixis (EXEL) Announces Presentation of Cobimetinib, Vemurafenib, Atezolizumab Combo Phase 1b Data in BRAF V600October 7, 2016 7:38 AM Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary TumorsOctober 7, 2016 7:36 AM